Get started
Author

Adolfo de la Fuente Burguera

Observed names: A. De la Fuente Burguera, A. De la Fuente Burguera, A. de la Fuente Burguera, Adolfo De La Fuente Burguera, Adolfo De la Fuente Burguera, Adolfo de la Fuente Burguera
OpenAlex ID: A5034819595
Immunotherapy in Acute Myeloid Leukemia: Where We Stand
2021 · Alessandro Isidori, Claudio Cerchione, et al. · Frontiers in Oncology · 94
PDF
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
2021 · Christian Récher, Christoph Röllig, et al. · Leukemia · 63
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes
2021 · Gail J. Roboz, Karen Yee, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 32
PDF
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
2023 · Rory M Shallis, Naval Daver, et al. · The Lancet Haematology · 17
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
2022 · Emilie Bérard, Christoph Röllig, et al. · Blood Cancer Journal · 10
Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia
2025 · Naval Daver, Anjali Advani, et al. · Blood · 8
PDF
Clinical outcomes after CPX ‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry
2023 · Teresa Bernal, Ainhoa Fernández Moreno, et al. · Cancer Medicine · 8
PDF
Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients with Prior Exposure to BTK Inhibitor
2024 · Grzegorz S. Nowakowski, Anna Paulina Dabrowska-Iwanicka, et al. · Blood · 5
PDF
Trial in Progress: A Phase 1b Single-Arm, Open-Label Study of Emavusertib (CA-4948) in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease
2023 · Adolfo De La Fuente Burguera, Claudio Cerchione, et al. · Blood · 4
An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms.
2022 · Raajit Rampal, Sundra Ramanathan, et al. · Journal of Clinical Oncology · 4
Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients
2024 · Eric S. Winer, David Sallman, et al. · Blood · 3
PDF
Stellae-123 gene expression signature improved risk stratification in Taiwanese acute myeloid leukemia patients
2024 · Yu-Hung Wang, Adrián Mosquera Orgueira, et al. · Scientific Reports · 3
Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia
2022 · Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, et al. · Frontiers in Oncology · 3
Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL).
2024 · Christian Grommes, Han W. Tun, et al. · Journal of Clinical Oncology · 2
Preliminary pharmacokinetic and MRD results from AML patients treated with 7- and 14-day dosing schedule of emavusertib added to combination therapy with azacitidine and venetoclax
2025 · Cristina Papayannidis, Ulf Schnetzke, et al. · Blood · 1
PDF
River-81: A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess Safety, PK, PD, Clinical Efficacy of RVU120 in Combination with Venetoclax in Patients with AML Failing Prior Venetoclax Plus Hypomethylating Agent Therapy
2024 · Maria Benedetta Giannini, Adolfo De la Fuente Burguera, et al. · Blood · 1
A phase 1 single-arm, open-label study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in patients (pts) with acute myeloid leukemia (AML) in complete response (CR) with measurable residual disease (MRD).
2024 · Adolfo de la Fuente Burguera, Claudio Cerchione, et al. · Journal of Clinical Oncology · 1
Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia
2023 · Gaspar Aspas Requena, Pierre Yves Dumas, et al. · Blood · 1
Efficacy and Safety of Ibrutinib in Combination With Rituximab as Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma. Results of the Geltamo Imcl‐2015 Study
2021 · E. Giné, F. De la Cruz, et al. · Hematological Oncology · 1
PDF
Pb1747 Assessment of Flt3 Mutation in Acute Myeloid Leukemia: Results of a Spanish Delphi Panel Survey
2019 · M.T. Gómez‐Casares, A. De la Fuente Burguera, et al. · HemaSphere · 1
Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China
2017 · Xiao Jun Huang, Kaiyan Liu, et al. · Oncotarget · 1
PDF
Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia
2023 · Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, et al. · Frontiers in Oncology
PDF
POSTER: AML-391 WHO and ICC 2022 Cytogenetic Abnormalities Defining Acute Myelogenous Leukemia (AML) Myelodysplasia-Related in First-Line Decitabine in Unfit AML Patients
2023 · Alicia Ortiz Lopez, Montesinos Pau, et al. · Clinical Lymphoma Myeloma & Leukemia
PDF
POSTER: IBCL-265 Compassionate Use of Plitidepsin in Patients With Non-Hodgkin Lymphoma (NHL) and SARS-CoV-2 Infection
2023 · Alicia Ortiz Lopez, Elena Saiz Lou, et al. · Clinical Lymphoma Myeloma & Leukemia
AML-391 WHO and ICC 2022 Cytogenetic Abnormalities Defining Acute Myelogenous Leukemia (AML) Myelodysplasia-Related in First-Line Decitabine in Unfit AML Patients
2023 · Alicia Ortiz Lopez, Montesinos Pau, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 29
Citation count: 263
H-index: 7
I10-index: 5
Year
Topic
Type